Literature DB >> 30375202

Persistent Fetal Vasculature.

Chonglin Chen1, Hu Xiao1, Xiaoyan Ding1.   

Abstract

During development, the fetal vasculature nourishes the developing lens and retina, and it subsequently regresses after the formation of the retinal vessels. Persistent fetal vasculature (PFV) occurs as a result of a failure of fetal ocular vasculature to undergo normal programmed involution, which leads to blindness or serious loss of vision. Persistent fetal vasculature is responsible for as much as 5% of childhood blindness in western countries. The regulatory mechanisms responsible for fetal vascular regress remain obscure, as do the underlying causes of the failure of regression. Because of recent advancements in microinvasive surgical techniques, the early treatment of PFV has become safer and more effective, thus paving the way for the development of a future new treatment strategy. In this review, clinical and imaging manifestations of PFV and the progress in the treatment of PFV are highlighted. Copyright 2019 Asia-Pacific Academy of Ophthalmology.

Entities:  

Keywords:  child; persistent fetal vasculature; vitreous body

Mesh:

Year:  2018        PMID: 30375202     DOI: 10.22608/APO.201854

Source DB:  PubMed          Journal:  Asia Pac J Ophthalmol (Phila)        ISSN: 2162-0989


  3 in total

1.  Ocular development in children with unilateral congenital cataract and persistent fetal vasculature.

Authors:  Shu-Yi Zhang; Hui Chen; Jing-Hui Wang; Wan Chen; Qi-Wei Wang; Jing-Jing Chen; Xiao-Shan Lin; Zhuo-Ling Lin; Duo-Ru Lin; Hao-Tian Lin; Wei-Rong Chen
Journal:  Int J Ophthalmol       Date:  2022-03-18       Impact factor: 1.779

2.  Outcomes and surgical management of persistent fetal vasculature.

Authors:  Nikhila Khandwala; Cagri Besirli; Brenda L Bohnsack
Journal:  BMJ Open Ophthalmol       Date:  2021-04-29

3.  Idiopathic lenticular surface neovascularization: An unusual presentation.

Authors:  Manoj Soman; Indu J Nair; Ramya R Nadig; Jay U Sheth; Unnikrishnan Nair
Journal:  Am J Ophthalmol Case Rep       Date:  2021-11-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.